share_log

华仁药业(300110.SZ):解聘洪亮执行总裁职务

Huaren Pharmaceutical (300110.SZ): Termination of the president position of Hong Liang.

Gelonghui Finance ·  Dec 27 16:01

On December 27, Grady Group reported that Huaren Pharmaceutical (300110.SZ) convened the sixth (temporary) meeting of the eighth Board of Directors on December 27, 2024, and approved the proposal regarding the dismissal of the company's executive president. According to the needs of the company's Operation management, and after the review by the Board of Directors Nomination Committee, the Board of Directors agreed to dismiss Mr. Hong Liang from the position of executive president, effective from the date of approval by this Board of Directors. After the dismissal, Mr. Hong Liang will no longer hold any position in the company, and this dismissal will not adversely affect the normal operation of the company's daily production and business activities. Mr. Hong Liang's original term was set to end on September 11, 2026. As of the date of this announcement, Mr. Hong Liang does not hold any shares in the company and there are no unfulfilled commitments that should be fulfilled.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment